Tesamorelin's Cognitive Effects: An Unexpected Finding
Tesamorelin
117% IGF-1 rise
Twenty weeks of tesamorelin (1 mg/day) increased IGF-1 levels by 117% in older adults and improved executive function in both healthy volunteers and those with mild cognitive impairment.
Baker et al., Archives of Neurology, 2012
Baker et al., Archives of Neurology, 2012
View as imageTesamorelin was developed to reduce visceral fat in HIV lipodystrophy. Nobody expected it to improve brain function. But when researchers at the University of Washington tested tesamorelin for 20 weeks in older adults with and without mild cognitive impairment, the cognitive improvements were the most striking finding of the trial. Executive function improved. Brain GABA levels increased across all measured regions. A metabolite linked to Alzheimer's disease decreased.[1] These results turned a metabolic drug into a candidate for cognitive aging research. For the full picture of tesamorelin as a GHRH analog, see our comprehensive tesamorelin overview.
Key Takeaways
- A 20-week RCT of tesamorelin (1 mg/day) in 152 older adults (ages 55-87) improved executive function tests of response inhibition and set-shifting in both MCI patients and healthy controls (Baker et al., 2012)
- IGF-1 levels increased by 117% from baseline while remaining within the physiological range (Baker et al., 2012)
- Brain GABA levels increased across frontal, parietal, and occipital regions after 20 weeks of GHRH administration; myo-inositol (an Alzheimer's-linked osmolyte) decreased in the posterior cingulate (Friedman et al., 2013)
- A 2025 study in people with HIV and abdominal obesity showed a trend toward improved neurocognitive performance after 6 months of tesamorelin, though between-group differences did not reach significance (Ellis et al., 2025)
- Adults with MCI showed a trend toward improved verbal memory, suggesting GHRH may have particular benefit for those at risk of Alzheimer's progression (Baker et al., 2012)
- Body fat decreased by 7.4% in the tesamorelin group, raising the question of whether cognitive improvements were driven by metabolic changes or direct neural effects
The Baker 2012 trial: how a fat-loss drug was tested for cognition
The rationale was straightforward. Growth hormone secretion declines with age. IGF-1 levels drop in parallel. Both GH and IGF-1 have documented neuroprotective and neurotrophic effects. If restoring the GH/IGF-1 axis to youthful levels improves brain function, a GHRH analog should be the cleanest test of that hypothesis: it stimulates endogenous GH production rather than delivering exogenous hormone.
Baker and colleagues (2012) randomized 152 adults aged 55-87 (59% women) to tesamorelin 1 mg/day or placebo, administered subcutaneously 30 minutes before bedtime for 20 weeks.[1] The cohort included both healthy older adults and adults diagnosed with amnestic mild cognitive impairment (aMCI), the clinical stage that often precedes Alzheimer's dementia.
The primary cognitive outcomes were composites of executive function and verbal memory, assessed through standardized neuropsychological testing before and after treatment.
Executive function: clear improvement
Tesamorelin produced a statistically significant improvement in executive function, specifically on tests measuring response inhibition (Stroop test) and set-shifting (Trail Making Test Part B). These improvements occurred in both the healthy older adults and the MCI group. The effect size was modest but consistent across subgroups.
Executive function is mediated primarily by the prefrontal cortex and its connections to other brain regions. Age-related decline in executive function precedes memory loss in many people and predicts functional independence. An intervention that improves executive function in older adults, even modestly, would have significant clinical implications if sustained.
Verbal memory: a trend in MCI
For verbal memory, the overall treatment effect was not statistically significant. However, adults with MCI showed a trend toward improved verbal memory that approached significance. This differential response makes biological sense: MCI patients have more room for improvement, and the hippocampal circuits that support verbal memory are particularly sensitive to IGF-1 signaling.
IGF-1 elevation: 117% increase
Tesamorelin raised IGF-1 levels by 117% from baseline. This is a dramatic increase, but the absolute levels remained within the physiological range for younger adults. The study was designed to restore IGF-1 to youthful levels, not to push it into supraphysiological territory. Higher IGF-1 levels were associated with greater improvements in executive function scores, suggesting a dose-response relationship between IGF-1 restoration and cognitive benefit.
Body composition changes
The tesamorelin group experienced a 7.4% reduction in body fat. This is relevant because visceral adiposity is independently associated with cognitive decline, insulin resistance, and neuroinflammation. Whether the cognitive improvements were driven by direct neural effects of GH/IGF-1 or by indirect improvements in metabolic health (less visceral fat, better insulin sensitivity) cannot be determined from this single trial.
Brain GABA: the neurochemical evidence
Friedman and colleagues (2013) published the companion neuroimaging analysis from the Baker trial, examining brain metabolite levels using magnetic resonance spectroscopy (MRS).[2]
After 20 weeks of tesamorelin, three neurochemical changes were observed:
GABA increased across all measured brain regions (frontal, parietal, occipital cortex). GABA is the primary inhibitory neurotransmitter. Its levels decline with age, and this decline is associated with reduced cognitive performance, particularly on executive function tasks that require filtering irrelevant information and maintaining attention. The fact that tesamorelin increased GABA levels aligns perfectly with the executive function improvements seen in the behavioral data.
N-acetylaspartylglutamate (NAAG) increased in the dorsolateral frontal cortex. NAAG is a neuromodulator that influences glutamate signaling. The dorsolateral prefrontal cortex is the primary brain region for executive function, so increased NAAG in this specific region is topographically consistent with the cognitive benefits observed.
Myo-inositol decreased in the posterior cingulate. This finding generated the most discussion. Myo-inositol is an osmolyte that is elevated in the brains of Alzheimer's patients. It is considered a marker of glial activation and possibly of early neuroinflammation. Its reduction after tesamorelin treatment suggests the drug may influence processes relevant to Alzheimer's pathology, not just normal aging.
These neurochemical changes were similar in the MCI group and healthy controls, indicating that GHRH treatment affects brain chemistry regardless of baseline cognitive status.
The HIV cognition connection
Tesamorelin's cognitive story gained a second chapter in 2025. Ellis and colleagues tested tesamorelin in people with HIV and abdominal obesity, a population where both metabolic dysfunction and neurocognitive impairment are common.[3]
In this population, abdominal obesity is linked to neurocognitive impairment through visceral adiposity, chronic inflammation, and reduced IGF-1. Tesamorelin addresses all three: it reduces visceral fat, modulates inflammatory markers, and increases IGF-1.
The tesamorelin group showed a trend toward improved neurocognitive performance after 6 months. The between-group difference did not reach statistical significance, but the direction was consistent with the Baker findings. The study was relatively small and the HIV population introduces confounders (antiretroviral drug effects, chronic immune activation) that may dilute a cognitive signal.
For the metabolic context of tesamorelin in HIV, see tesamorelin and HIV lipodystrophy.
Metabolic improvements: the cognitive bridge
Understanding tesamorelin's cognitive effects requires understanding its metabolic effects, because the two may be inseparable.
Falutz et al. (2010) established that tesamorelin significantly reduces visceral adipose tissue in HIV-infected patients with abdominal fat accumulation.[4] Stanley et al. (2012) showed this visceral fat reduction was associated with improved metabolic profiles including better insulin sensitivity and lipid parameters.[5]
Makimura et al. (2014) demonstrated tesamorelin improved phosphocreatine recovery (a measure of mitochondrial function) in obese subjects with reduced GH.[6] Adrian et al. (2019) showed tesamorelin decreased muscle fat and increased lean body mass.[7]
Each of these metabolic improvements is independently associated with better cognitive function in epidemiological studies. Less visceral fat means less neuroinflammation. Better insulin sensitivity means better brain glucose utilization. Improved mitochondrial function means better neuronal energy metabolism. The cognitive benefits observed in the Baker trial may represent the cumulative effect of systemic metabolic optimization, with direct GH/IGF-1 effects on the brain adding an additional layer.
Badran et al. (2026) published a meta-analysis confirming tesamorelin's favorable body composition and metabolic effects across multiple trials.[8] The consistency of metabolic benefit provides a plausible substrate for cognitive improvement.
GHRH and Alzheimer's: the preclinical context
The interest in GHRH for cognition is not based solely on the Baker trial. Preclinical research supports a role for GHRH signaling in neurodegenerative disease.
Jaszberenyi et al. (2012) showed that GHRH antagonists had beneficial effects in animal models of Alzheimer's disease.[9] This may seem paradoxical (antagonists helping where agonists also help), but GHRH signaling in the brain is complex and context-dependent. The antagonist effects may involve anti-inflammatory pathways distinct from the GH-releasing function.
Barabutis et al. (2020) demonstrated GHRH antagonists protect against hydrogen peroxide-induced breakdown of brain microvascular endothelial cells, suggesting a role in blood-brain barrier integrity.[10]
These findings indicate that the GHRH receptor system in the brain has functions beyond GH release that may be relevant to neurodegeneration. Tesamorelin's cognitive effects could involve both the classical GH/IGF-1 pathway and direct GHRH receptor signaling in neural tissue.
For readers interested in how other peptides affect cognition, sermorelin is a related GHRH analog, and the nootropic peptide landscape includes several peptides with cognitive research.
What the evidence does not show
One trial. The Baker 2012 study is essentially the only randomized, placebo-controlled trial of tesamorelin for cognition. The Friedman 2013 paper is a companion analysis from the same cohort. The Ellis 2025 study in HIV did not reach significance. One positive RCT, no matter how well designed, requires replication before the finding is considered established.
Twenty weeks is short. Whether the cognitive improvements persist beyond 20 weeks, increase with longer treatment, or reverse after discontinuation is unknown. Age-related cognitive decline progresses over years and decades. A 20-week snapshot cannot establish long-term trajectory modification.
The mechanism is unclear. Is it the IGF-1? The GABA? The reduced visceral fat? The improved insulin sensitivity? The direct GHRH receptor activation in the brain? The trial design cannot isolate which of these concurrent changes drove the cognitive improvement. Until mechanism-specific studies are conducted, the cognitive benefit remains an observation without a clear pharmacological explanation.
No Alzheimer's prevention data. The myo-inositol reduction in the posterior cingulate is suggestive but does not constitute evidence that tesamorelin prevents or slows Alzheimer's disease progression. That would require long-duration trials with clinical Alzheimer's endpoints, which have not been conducted.
MCI-specific effects are trends, not proven. The verbal memory improvement in MCI patients was a trend, not a statistically significant result. Reporting it as evidence of Alzheimer's benefit would overstate the data.
The Bottom Line
A 20-week randomized controlled trial demonstrated that tesamorelin improved executive function in both healthy older adults and those with mild cognitive impairment, while raising brain GABA levels and reducing the Alzheimer's-linked metabolite myo-inositol. IGF-1 increased by 117% within physiological range. A 2025 HIV study showed a non-significant trend in the same direction. The findings are based on a single trial and require replication. Whether cognitive benefits stem from direct neural effects, metabolic improvement, or both remains undetermined.